Spots Global Cancer Trial Database for Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research

Official Title: A Prospective Study to See if Cardiac Effects of Herceptin Can be Prevented With Standard Heart Medications

Study ID: NCT01016886

Conditions

Breast Cancer

Heart Failure

Interventions

perindopril OR bisoprolol OR placebo

Study Description

Brief Summary: While trastuzumab has been shown to prevent recurrences of breast cancer, some women may also experience damage to their heart muscle (including heart failure) as a result of their treatment. The investigators hope to learn if standard medications used in heart failure can prevent heart damage caused by trastuzumab in women with breast cancer. The investigators would also like to know if there are any ways to detect this damage earlier using magnetic resonance imaging (MRI) and blood tests.

Detailed Description: We propose a randomized, placebo-controlled, double-blind study evaluating the efficacy of an ACE-inhibitor (perindopril) or a beta blocker (bisoprolol) for the prevention of LV remodeling among women with early breast cancer scheduled for chemotherapy and one year of trastuzumab. Participants will undergo cardiac MRI at baseline and 3 and 12 months, replacing the usual MUGA, as well as a post-treatment cardiac MRI at 24 months to evaluate long-term effect.